Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Tempe, Arizona • Concord, California • Fresno, California + 22 more

Conditions: Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
Interventions: Intensive glycemic targets, Standard glycemic targets; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Norman, Oklahoma + 2 more

Conditions: Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), T2DM (Type 2 Diabetes Mellitus), T2D, T2DM, Remote Patient Monitoring, Artificial Intelegence
Interventions: Fitbit and AI Chatbot, Routine Care; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ovarian Cancer
Interventions: carboplatin, paclitaxel, Avelumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 146
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more

Conditions: Type 1 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions: cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing; Drug · Biological · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PreDiabetes, Blood Glucose, High
Interventions: Cinnamon, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 20 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Head and Neck Cancer
Interventions: gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy; Genetic · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gestational Diabetes Mellitus
Interventions: Standard Glucola GCT, Twizzlers challenge; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec/insulin aspart, insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 30
States / cities: La Mesa, California • Lancaster, California • Mission Hills, California + 25 more

Conditions: Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia, CAH - 21-Hydroxylase Deficiency
Interventions: SPR001; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Orange, California • San Diego, California • Atlanta, Georgia + 5 more

Conditions: Secondary Hyperparathyroidism
Interventions: Teriparatide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years to 59 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Ovarian Cancer
Interventions: questionnaire, interview; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes
Interventions: Diabetes Digital Intervention, Generic Digital Intervention; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 94,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Pancreatic Cancer
Interventions: Onvansertib, NALIRIFOX; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions: Relamorelin, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 70
States / cities: Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more

Conditions: Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
Interventions: Medically Tailored Meals; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Denver, Colorado • Lafayette, Colorado

Conditions: Autism Spectrum Disorder (ASD), Cardiometabolic Health Indicators, Cardiometabolic Risk Factors, Metabolic Syndrome, Prediabetes
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pediatric Obesity, Type 2 Diabetes, Time Restricted Eating
Interventions: Time Limited Eating, Components Common to All Study Arms., Control, Continuous Glucose Monitor; Behavioral · Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 21 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiopulmonary Arrest, Cardiac Arrest
Interventions: Vasopressin, Epinephrine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bardet-Biedl Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions: PD-0332991; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more

Search by objective public record fields.

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Investigation of Cinnamon Spice on Glucose Tolerance in Subjects With Pre-diabetes

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk

Influenza Vaccination Digital Interventions for People Living With Diabetes

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

This Study Will Evaluate Cardiorespiratory and Muscular Fitness to Examine Associations With Anthropometric Characteristics and Other Indicators of Cardiometabolic Risk Among Patients With or Without Autism Spectrum Disorder

Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)

Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research